Lilly’s cardiovascular outcomes trial is the first to use an active comparator, finding noninferiority but not superiority of tirzepatide to dulaglutide in CV outcomes.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/tirzepatides-heart-benefit-similar-dulaglutides-2025a1000ovi?src=rss
Author :
Publish date : 2025-09-18 21:39:00
Copyright for syndicated content belongs to the linked Source.
